4.71
Corvus Pharmaceuticals Inc stock is traded at $4.71, with a volume of 404.91K.
It is down -0.84% in the last 24 hours and up +14.32% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$4.75
Open:
$4.75
24h Volume:
404.91K
Relative Volume:
0.39
Market Cap:
$321.08M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-8.4107
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+10.43%
1M Performance:
+14.32%
6M Performance:
-10.80%
1Y Performance:
+103.90%
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CRVS
Corvus Pharmaceuticals Inc
|
4.71 | 366.29M | 0 | -27.03M | -23.97M | -0.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-02-25 | Initiated | H.C. Wainwright | Buy |
Aug-18-23 | Initiated | Oppenheimer | Outperform |
Dec-01-21 | Resumed | Jefferies | Buy |
May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
Sep-12-19 | Initiated | Mizuho | Buy |
May-29-19 | Initiated | ROTH Capital | Buy |
Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-18-16 | Initiated | Credit Suisse | Outperform |
Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
What drives Corvus Pharmaceuticals Inc. stock priceSuperior profit margins - PrintWeekIndia
What makes Corvus Pharmaceuticals Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Corvus Pharma Bets On Immunotherapy And Analyst Optimism - Finimize
What analysts say about Corvus Pharmaceuticals Inc. stockPhenomenal capital gains - jammulinksnews.com
Is Corvus Pharmaceuticals Inc. a good long term investmentFree AI-Backed Trading Signals - jammulinksnews.com
Corvus Pharmaceuticals Inc. Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser
How Corvus Pharmaceuticals Inc. stock performs during market volatilityDaily Breakout Picks - Newser
Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says - MarketScreener
Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis - TipRanks
Corvus Pharmaceuticals: Insider Confidence and Clinical Catalysts Fueling Growth - AInvest
OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million By Investing.com - Investing.com Canada
Corvus Pharmaceuticals, Inc.(NasdaqGM: CRVS) added to Russell 3000 Index - MarketScreener
Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News - GuruFocus
Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan
Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX
Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha
Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq
Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener
Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia
Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com
Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Exclusive: Corvus Pharmaceuticals Reveals Latest Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corvus Pharmaceuticals Inc Stock (CRVS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Thompson Peter A. | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
Jones William Benton | See Remarks |
Jun 04 '25 |
Option Exercise |
3.50 |
19,357 |
67,750 |
173,130 |
MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):